CRINETICS PHARMACEUTICALS, INC.

Profile

Company Names

CRINETICS PHARMACEUTICALS, INC.

Addresses

6055 LUSK BOULEVARD, SAN DIEGO, CA 92121

6197 CORNERSTONE COURT, SUITE 111, SAN DIEGO, CA 92121

Phone Numbers

858-450-6464

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY, PHARMACEUTICALS

Year Incorporated:

> 5 years ago

State Incorporated:

DELAWARE

Total Amount Raised:

$428,000,028.00

Number of Funding Rounds:

3
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
3
2024-03-01 
$350,000,028.00 
$350,000,028.00 
$0.00 
Equity 
2
2018-02-09 
$59,999,999.00 
$65,000,001.00 
$5,000,002.00 
Equity 
1
2015-10-30 
$18,000,001.00 
$40,000,004.00 
$22,000,003.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
CAMILLE 
 
BEDROSIAN, M.D. 
DIRECTOR
CRINETICS PHARMACEUTICALS, INC.
STEPHEN 
 
BETZ 
EXECUTIVE OFFICER
CRINETICS PHARMACEUTICALS, INC.
STEPHEN 
F. 
BETZ 
EXECUTIVE OFFICER
CRINETICS PHARMACEUTICALS, INC.
ROGERIO 
VIVALDI 
COELHO, M.D. 
DIRECTOR
CRINETICS PHARMACEUTICALS, INC.
CAREN 
 
DEARDORF 
DIRECTOR
CRINETICS PHARMACEUTICALS, INC.   |  NEUROSENSE THERAPEUTICS LTD.
MASON 
 
FREEMAN 
DIRECTOR
CRINETICS PHARMACEUTICALS, INC.
MASON 
 
FREEMAN, M.D. 
DIRECTOR
CRINETICS PHARMACEUTICALS, INC.
MATTHEW 
 
FUST 
DIRECTOR
DERMIRA, INC.   |  ARSENAL BIOSCIENCES, INC.   |  NEUMORA THERAPEUTICS, INC.   |  CRINETICS PHARMACEUTICALS, INC.   |  STAR THERAPEUTICS LLC   |  ELECTRA THERAPEUTICS, INC.
MATTHEW 
K. 
FUST 
DIRECTOR
SUNESIS PHARMACEUTICALS INC   |  DERMIRA, INC.   |  CRINETICS PHARMACEUTICALS, INC.
JAMES 
 
HASSARD 
EXECUTIVE OFFICER
CRINETICS PHARMACEUTICALS, INC.
STEVE 
 
KALDOR 
DIRECTOR
CRINETICS PHARMACEUTICALS, INC.
STEVE 
 
KALDOR, PH.D 
DIRECTOR
CRINETICS PHARMACEUTICALS, INC.
JEFF 
 
KNIGHT 
EXECUTIVE OFFICER
CRINETICS PHARMACEUTICALS, INC.
WESTON 
 
NICHOLS, PH.D 
DIRECTOR
CRINETICS PHARMACEUTICALS, INC.
WESTON 
 
NICHOLS, PHD 
DIRECTOR
CRINETICS PHARMACEUTICALS, INC.
JACK 
B. 
NIELSEN 
DIRECTOR
NEOMEND INC   |  REATA PHARMACEUTICALS INC   |  MERUS N.V.   |  CRINETICS PHARMACEUTICALS, INC.
STEPHANIE 
 
OKEY 
DIRECTOR
CRINETICS PHARMACEUTICALS, INC.
DANA 
 
PIZZUTI 
EXECUTIVE OFFICER
CRINETICS PHARMACEUTICALS, INC.
MAHENDRA 
 
SHAH 
DIRECTOR
AVADHI FINANCE + TECHNOLOGY INC   |  CRINETICS PHARMACEUTICALS, INC.   |  VIVO PANDA FUND, L.P.   |  BOLT BIOTHERAPEUTICS, INC.   |  IMPEL NEUROPHARMA INC   |  HOMOLOGY MEDICINES, INC.   |  SOLENO THERAPEUTICS INC   |  CEREBRAL THERAPEUTICS, INC.   |  VERONA PHARMA PLC   |  SCIENTIA VASCULAR, INC.
RICHARD 
SCOTT 
STRUTHERS 
EXECUTIVE OFFICER, DIRECTOR
CRINETICS PHARMACEUTICALS, INC.
RICHARD 
SCOTT 
STRUTHERS, PH.D 
EXECUTIVE OFFICER, DIRECTOR
CRINETICS PHARMACEUTICALS, INC.
RICHARD 
SCOTT 
STRUTHERS, PHD 
EXECUTIVE OFFICER, DIRECTOR
CRINETICS PHARMACEUTICALS, INC.
WENDELL 
 
WIERENGA 
DIRECTOR
XENOPORT INC   |  CRINETICS PHARMACEUTICALS, INC.   |  APRICUS BIOSCIENCES, INC.   |  DERMATA THERAPEUTICS, LLC   |  DERMATA THERAPEUTICS, INC.
WENDELL 
 
WIERENGA, PH.D 
DIRECTOR
CRINETICS PHARMACEUTICALS, INC.
WENDELL 
 
WIERENGA, PHD 
DIRECTOR
CRINETICS PHARMACEUTICALS, INC.
MARC 
 
WILSON 
EXECUTIVE OFFICER
APPIAN CORP   |  CRINETICS PHARMACEUTICALS, INC.
YUNFEI 
 
ZHU 
EXECUTIVE OFFICER
CRINETICS PHARMACEUTICALS, INC.   |  RADIONETICS ONCOLOGY, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2024-03-11
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2024-03-01 
2018-02-23
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2018-02-09 
2015-11-16
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2015-10-30 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
LEERINK PARTNERS LLC
39011
PIPER SANDLER + CO.
NONE
PIPER SANDLER + CO.
665
NONE
NONE
ROBERT W. BAIRD + CO. INCORPORATED
8158
NONE
NONE
CITIZENS JMP SECURITIES, LLC
22208
NONE
NONE
H.C. WAINWRIGHT + CO., LLC
375
NONE
NONE
LIFESCI CAPITAL, LLC
168404